A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
Latest Information Update: 04 Apr 2024
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 26 May 2021 Status changed from active, no longer recruiting to completed.
- 06 Feb 2020 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2025.
- 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.